“503A” and “503B” come up constantly in peptide regulation news, but the two terms describe very different things. Here is a clear, non-legal explainer of the two compounding pathways and why the distinction keeps appearing in peptide headlines. Two different compounding pathways Both 503A and 503B refer to sections of the Federal Food, Drug, and…
If you follow peptide research, you have probably seen headlines about an FDA advisory meeting in July 2026. Here is a plain-language guide to what the Pharmacy Compounding Advisory Committee (PCAC) actually does, what “503A” means, and why none of it is a simple yes-or-no on whether a peptide is “approved.” What is PCAC? The…
The parts of a U-100 insulin syringe and how the unit scale maps to volume.
Reconstituted peptide shelf life explained: why mixed peptides last only days to weeks, what beyond-use dating means, and how to store and label them.
GHRH vs GHRP explained: how GHRH analogs (sermorelin, CJC-1295) differ from GH secretagogues (ipamorelin, GHRP-2, MK-677), and why they are combined.
A balanced, sourced look at growth hormone peptide side effects — fluid retention, joint aches, higher blood sugar and appetite — and why they happen.
How mg, mL, and mg/mL relate, with worked lab-math examples.
As scrutiny of research-peptide quality grows, one principle keeps surfacing: a Certificate of Analysis (COA) is only meaningful when it is tied to the exact batch in hand and reports more than a single purity figure. A useful COA generally documents several things together: identity confirmation (commonly by mass spectrometry), purity (typically by HPLC), and…
A peer-reviewed study in the International Journal of Obesity compares three GLP-1–class peptides — semaglutide, tirzepatide, and retatrutide — in a genetic mouse model of obesity. The researchers used MC4R-knockout mice, which lack a receptor central to the brain’s appetite-regulating melanocortin pathway and develop obesity, insulin resistance, and markers of liver stress. Over a 21-day…
Eli Lilly has reported topline results from TRIUMPH-1, the first Phase 3 obesity trial of the triple-agonist peptide retatrutide. Retatrutide acts on three receptors — GLP-1, GIP, and glucagon — distinguishing it from single- and dual-agonist compounds in the same class. According to the company’s announcement, mean body-weight reduction rose with dose: roughly 19% at…
